Long-term efficacy of adalimumab in hyper- immunoglobulin d and periodic fever syndrome

Israel Medical Association Journal

Volumn 16, Issue 10, 2014, Pages 605-607

  Gangi, Marcella Di ^a   Amato, Giorgio ^a   Converso, Giovanni ^a   Benenati, Alessia ^a   Leonetti, Concetta ^a   Borella, Elisabetta ^b   Doria, Andrea ^b   Foti, Rosario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adalimumab; Autoinflammatory syndrome; Hyper immunoglobulin D periodic fever syndrome (HIDS); Mevalonate kinase gene (MVK); Tumor necrosis factor alpha (TNF ) therapy

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYTOSKELETON PROTEIN; GENETIC MARKER; MARENOSTRIN; MEVALONATE KINASE; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADULT; ANTAGONISTS AND INHIBITORS; CASE REPORT; FEMALE; GENETIC MARKER; GENETICS; HUMAN; IMMUNOLOGY; MEVALONATE KINASE DEFICIENCY; MUTATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; REMISSION; SACROILIITIS; SEVERITY OF ILLNESS INDEX; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

ACUTE-PHASE REACTION; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; CYTOSKELETAL PROTEINS; FEMALE; GENETIC MARKERS; HUMANS; INJECTIONS, SUBCUTANEOUS; MAGNETIC RESONANCE IMAGING; MEVALONATE KINASE DEFICIENCY; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); REMISSION INDUCTION; SACROILIITIS; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908204555     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Frenkel J, Rijkers GT, Mandey SH et al. Lack of isoprenoid products raises ex vivo interleukin-1 beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2002; 46: 2794-803
2. Drenth JP, van Deuren M, Van der.Ven-Jongekrijg J, Schalkwijk CG, van der Meer JW. Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 1995; 85: 3586-93
3. Drenth JP, van der Meer JW, Kushner I. Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. J Immunol 1996; 157: 400-4
4. Duman I, Balaban B, Tugcu I, Dincer K. Familial Mediterranean fever unusually coexisted in an ankylosing spondylitis patient. MEFV mutation has any role? Rheumatol Int 2007; 27: 689-90
5. Kaushik P, el-Sobkie NI, Shehab D, Malaviya AN. Familial Mediterranean fever with HLA B-27 positive ankylosing spondylitis in a young Armenian man. Clin Exp Rheumatol 1999; 17: 387-8
6. Langevitz P, Livneh A, Zemer D, Shemer J, Pras M. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum 1997; 27:67-72
7. Kaşifoğlu T, Calişir C, Cansu DU, Korkmaz C. The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis. Clin Rheumatol 2009; 28: 41-6
8. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58: 1248-57
9. Bodar EJ, van der Hilst JC, van Heerde W, van der Meer JW, Drenth JP, Simon A. Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood 2007; 109: 2416-18. Epub 2006 Nov 30
10. Kraus CL, Culican SM. Nummular keratopathy in a patient with Hyper-IgD Syndrome. Pediatr Rheumatol Online J 2009; 5: 7:14